Continue Reading
-
Ribbon Bio and Syngoi Technologies Commence Strategic Collaboration to Advance Gene Therapies with Synthetic DNA
Collaboration builds upon Syngoi’s synthetic DNA manufacturing capabilities and Ribbon’s algorithm-driven technology to produce pristine…
Continue Reading -
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of…
Continue Reading -
Neuro Event Labs Oy raises €2.0M investment for commercial expansion in Europe and US market entry of its AI-powered seizure detection device for epilepsy.
Tampere, Finland – 12 February 2025: Neuro Event Labs Oy today announced it has raised…
Continue Reading -
Neuro Event Labs, Nelli® officially received European MDR (Medical Device Regulation) certification as a Class IIa medical device
Great news from Neuro Event Labs Oy, as Nelli®, their AI-powered seizure detection and characterization…
Continue Reading -
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic…
Continue Reading -
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on…
Continue Reading -
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878
Transition into clinical-stage development marks a significant corporate and R&D milestone. Munich, Germany, October 17,…
Continue Reading -
Step Pharma announces first patient dosed in a phase 1 trial of dencatistat for patients with solid tumours
Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today…
Continue Reading -
Alex Therapeutics has signed an exclusive agreement with Navamedic
Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion…
Continue Reading